The global major depressive disorder market size was valued at around USD XX in 2021 and is estimated to reach USD XX by 2030, expanding at a CAGR of around XX% during the forecast period, 2022 – 2030. The growth of the market is attributed to the imbalanced work-life and continuously changing lifestyle.
Major depressive disorder, also known as clinical depression, refers to a medical condition, in which feeling of sadness and loss of interest persists. It is a mood disorder that affects how an individual thinks, feels, and behaves. It can lead to various physical and emotional problems, which affect the normal day-to-day activities of that individual. Individuals can suffer from various episodes of the disorder during their lifetime. Various symptoms indicate the start of these episodes. These symptoms include a feeling of sadness and hopelessness, angry outbursts, increasing frustrations, loss of interest, insomnia, tiredness or lack of energy, reduced appetite, anxiety, restlessness, slowed body movements, slowed thinking, self-blame, feeling of worthlessness, trouble in decision-making, suicidal thoughts, physical problems such as headaches, and others. Some individuals do not show the symptoms strongly. Some individuals suffer from grave symptoms that affect their daily life. Major depressive disorder can affect children, young adults, and adults as well. Seeking professional help to deal with major depressive disorder is always advisable.
The COVID-19 pandemic situation witnessed a surge in the major depressive disorder market, as the cases of depressive and anxiety disorders increased during the time. The pandemic highlighted the underlying symptoms of the disorder among several individuals. For example, major depressive disorder is considered a complex but common disorder with more than 3.5 million cases in Japan, affecting 3% of the population.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing demand for antidepressants is expected to drive the market during the forecast period.
- Rising cases of substance abuse and alcohol abuse are estimated to fuel the market in the coming years.
- Growing geriatric population across the globe spurs the market.
- Surging prevalence of anxiety disorders is projected to fuel the market during the forecast period.
- Increasing adoption of technologically advanced therapies in treating the major depressive disorder is anticipated to drive the market in the coming years.
- Lack of awareness regarding major depressive disorder is estimated to hamper the growth of the market during the forecast period.
- Research and development of new and innovative drugs offer growth opportunities to the market players.
Scope of the Report
The report on the global major depressive disorder market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Major Depressive Disorder Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2021
|
|
Historic Data
|
2019–2020
|
|
Forecast Period
|
2022–2030
|
|
Segmentation
|
Diagnosis (Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and Others), Treatments (Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), and Others), Drug-class (Antidepressant Drugs, Benzodiazepines, Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin & Norepinephrine Reuptake Inhibitors (SNRIs), and Others), and End-users (Clinics, Hospitals, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Bristol-Myers Squibb Company; Pfizer, Inc.; H. Lundbeck A/S; Sanofi S.A.; GSK plc; Merck & Co., Inc.; AstraZeneca; Forest Laboratories, Inc.; Johnson & Johnson Services, Inc.; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; and Others
|
Market Segment Insights
Psychiatric evaluations segment dominates the market
In terms of diagnosis, the market is segregated into physical examinations, laboratory tests, psychiatric evaluations, the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and others. The psychiatric evaluations segment is expected to hold a significant share in the global major depressive disorder share during the forecast period, due to growing awareness and acceptance of psychiatry facilities and psychiatrists across the globe. The DSM-5 segment is anticipated to expand during the forecast period, due to the growing usage of the DSM-5 among psychotherapists across the globe.
Psychotherapy segment holds a significant share of the market
Based on treatments, the market is divided into psychotherapy, medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), and others. The psychotherapy segment is estimated to hold a key market share during the forecast period, due to the increasing number of psychotherapists and psychotherapy facilities available across the globe. Several approaches to psychotherapy such as behavioral therapy, cognitive therapy, psychoanalysis, holistic therapy, and others are offered to meet the different needs of patients, which aid in the expansion of the segment. The medication segment is anticipated to expand during the forecast period, owing to increasing research and development activities in the medication sector for major depressive disorder.
Antidepressant drugs segment holds a key market share
Based on drug class, the market is segmented into antidepressant drugs, benzodiazepines, Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin & Norepinephrine Reuptake Inhibitors (SNRIs), and others. The antidepressant drugs segment is expected to hold a key market share during the forecast period, due to the increasing prevalence of major depressive disorder across the globe. Antidepressant drugs are a common and effective medication offered for the treatment of the disorder. Antidepressant drugs are available in a variety to suit the treatment, which makes them easy to procure with a prescription. These are the key factors that aid in the expansion of the segment.
Clinics segment witnesses a high CAGR
In terms of end-users, the market is divided into clinics, hospitals, and others. The clinics segment is estimated to expand at a rapid pace during the forecast period, owing to rising clinic visits of patients suffering from the disorder. The rising prevalence of major depressive disorder across the globe is the key factor, which drives the clinics segment.
North America dominates the market
On the basis of regions, the market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to register a high CAGR during the forecast period, due to increasing awareness regarding major depressive disorder, its negative effects on lives, and methods of treatment in the region. The increasing prevalence of major depressive disorder in North America is the key factor, which aids the expansion of the segment in the region. The market in North America holds around 92.8% of the share in 2021. According to the U.S. Department of Health and Human Services in 2020, around 17% of the population aged between 12 to 17 suffered from the r depressive disorder.
Segments
The global major depressive disorder market has been segmented on the basis of
Diagnosis
- Physical Examinations
- Laboratory Tests
- Psychiatric Evaluations
- Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
- Others
Treatments
- Psychotherapy
- Medications
- Electroconvulsive Therapy (ECT)
- Transcranial Magnetic Stimulation (TMS)
- Others
Drug-class
- Antidepressant Drugs
- Benzodiazepines
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin & Norepinephrine Reuptake Inhibitors (SNRIs)
- Others
End-users
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Bristol-Myers Squibb Company
- Pfizer, Inc.
- H. Lundbeck A/S
- Sanofi S.A.
- GSK plc
- Merck & Co., Inc.
- AstraZeneca
- Forest Laboratories, Inc.
- Johnson & Johnson Services, Inc.
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Others
Competitive Landscape
The major players in the global major depressive disorder market include Bristol-Myers Squibb Company; Pfizer, Inc.; H. Lundbeck A/S; Sanofi S.A.; GSK plc; Merck & Co., Inc.; AstraZeneca; Forest Laboratories, Inc.; Johnson & Johnson Services, Inc.; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; and others. They use strategies such as collaboration, mergers, partnerships, acquisitions, and product launches to strengthen their hold on the market. For example, in September 2018, H. Lundbeck A/S partnered with Takeda Pharmaceutical Company Limited, to submit a New Drug Application (NDA) for vortioxetine, to treat the major depressive disorder in adults, to the Health Ministry of Japan. In December 2019, AstraZeneca entered an agreement with Cheplapharm Arzneimittel GmbH, a Germany-based pharmaceutical company, to hand over commercial rights of Seroquel and Seroquel XR to Cheplapharm.
Request For Customization
Enquiry Before Buying
Speak With Analyst
